Matching articles for "olezarsen"
Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
The Medical Letter on Drugs and Therapeutics • April 13, 2026; (Issue 1752)
Plozasiran (Redemplo – Arrowhead), an apolipoprotein
C-III (apoC-III)-directed small interfering ribonucleic
acid (siRNA), has been approved by the FDA to
reduce triglyceride levels in adults with...
Plozasiran (Redemplo – Arrowhead), an apolipoprotein
C-III (apoC-III)-directed small interfering ribonucleic
acid (siRNA), has been approved by the FDA to
reduce triglyceride levels in adults with familial
chylomicronemia syndrome (FCS). It is the second
drug to be approved in the US for this indication; the
apoC-III-directed antisense oligonucleotide olezarsen
(Tryngolza) was approved in 2024.
Olezarsen (Tryngolza) for Familial Chylomicronemia Syndrome (online only)
The Medical Letter on Drugs and Therapeutics • March 3, 2025; (Issue 1723)
Olezarsen (Tryngolza – Ionis), an apolipoprotein C-III
(apoC-III)-directed antisense oligonucleotide, has
been approved by the FDA to reduce triglyceride levels
in adults with familial chylomicronemia...
Olezarsen (Tryngolza – Ionis), an apolipoprotein C-III
(apoC-III)-directed antisense oligonucleotide, has
been approved by the FDA to reduce triglyceride levels
in adults with familial chylomicronemia syndrome
(FCS). It is the first drug to be approved in the US for
this indication.